Get the Stockscreener App
2.68
3.94%
-0.11
Aptevo Therapeutics Inc stock is traded at $2.68, with a volume of 85,743.
It is down -3.94% in the last 24 hours and down -9.15% over the past month.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
See More
Previous Close:
$2.79
Open:
$2.73
24h Volume:
85,743
Relative Volume:
0.04
Market Cap:
$8.64M
Revenue:
$12.99M
Net Income/Loss:
$-23.72M
P/E Ratio:
-0.0276
EPS:
-97.2514
Net Cash Flow:
$-23.28M
1W Performance:
-12.42%
1M Performance:
-9.15%
6M Performance:
-96.94%
1Y Performance:
-99.10%
1-Day Range:
$2.65
$2.765
1-Week Range:
$2.65
$3.07
52-Week Range:
$2.65
$381.10
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics Inc
Sector
Industry
Phone
206-838-0500
Address
2401 4TH AVE., SEATTLE, WA
Compare APVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
2.68 | 9.00M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-05-17 | Resumed | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Stock (APVO) Latest News
What are the latest earnings results for Aptevo Therapeutics Inc.Chart Pattern Recommendation For Beginners - jammulinksnews.com
What institutional investors are buying Aptevo Therapeutics Inc. stockEarnings Report Alerts For Every Investor - jammulinksnews.com
What are the technical indicators suggesting about Aptevo Therapeutics Inc.Wealth Building Trend Scanner For Smart Trading - jammulinksnews.com
Why is Aptevo Therapeutics Inc. stock attracting strong analyst attentionFinancial News Data Feed With High Returns - jammulinksnews.com
Historical volatility pattern of Aptevo Therapeutics Inc. visualizedCapital Protection Trading Strategies Gain Interest - metal.it
Aptevo Therapeutics Inc. Shows Support at Fibonacci LevelFree Elite Traders Group - beatles.ru
How strong is Aptevo Therapeutics Inc. company’s balance sheetExplosive portfolio gains - jammulinksnews.com
How does Aptevo Therapeutics Inc. generate profit in a changing economyGet alerts on the hottest market movers - jammulinksnews.com
What is Aptevo Therapeutics Inc. company’s growth strategyInvest smarter with advanced market data - jammulinksnews.com
Should I hold or sell Aptevo Therapeutics Inc. stock in 2025Build a diversified portfolio for stability - jammulinksnews.com
Does Aptevo Therapeutics Inc. stock perform well during market downturnsUncover the best stocks for explosive growth - jammulinksnews.com
What are Aptevo Therapeutics Inc. company’s key revenue driversInvest smarter with comprehensive market analysis - jammulinksnews.com
How volatile is Aptevo Therapeutics Inc. stock compared to the marketTrack emerging stocks with high growth potential - jammulinksnews.com
How does Aptevo Therapeutics Inc. compare to its industry peersInvest smarter with comprehensive market analysis - jammulinksnews.com
Is it the right time to buy Aptevo Therapeutics Inc. stockDiscover market opportunities with real-time data - jammulinksnews.com
Is Aptevo Therapeutics Inc. a Top Dividend Stock to Watch in 2025Top Gaining Low Risk Assets - metal.it
Is Aptevo Therapeutics Inc. a growth stock or a value stockTransform your portfolio with high-yield stocks - jammulinksnews.com
Aptevo Therapeutics' Equity Offering: Strategic Opportunity or Investor Warning? - AInvest
Aptevo Therapeutics Inc. Stock Analysis and ForecastMarket-crushing profits - PrintWeekIndia
Aptevo Therapeutics Files Registration Statement for Share Resale by Stockholder - 富途牛牛
Aptevo Therapeutics' Share Resale and Its Implications for Liquidity and Shareholder Value - AInvest
Aptevo Therapeutics files to sell 8.25M shares of common stock for holders - MSN
Aptevo Therapeutics' $8M Share and Warrant Offering: Balancing Dilution with Strategic Clinical Development - AInvest
Aptevo Therapeutics (APVO) Schedules Offering of 8.25 Million Shares - GuruFocus
Is Aptevo Therapeutics Inc. a good long term investmentFast-track wealth growth - PrintWeekIndia
What analysts say about Aptevo Therapeutics Inc. stockHigh-profit stock alerts - PrintWeekIndia
Is Aptevo Therapeutics Inc. stock a growth or value playRapid market gains - jammulinksnews.com
What drives Aptevo Therapeutics Inc. stock priceFree Stock Selection - PrintWeekIndia
Aptevo Therapeutics shareholders approve all proposals at annual meeting By Investing.com - Investing.com Canada
Aptevo Therapeutics shareholders approve all proposals at annual meeting - Investing.com
Aptevo Therapeutics Holds Annual Stockholders Meeting - TipRanks
Will Aptevo Therapeutics Inc. stock benefit from AI tech trendsExceptional risk-adjusted gains - jammulinksnews.com
Aptevo Therapeutics Inc Stock (APVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):